NCT02383212

Disease Type: Solid Tumor
Status: Open

Trial Information

A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death – 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients with Advanced Malignancies

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

For more information, please contact: